Results 11 to 20 of about 15,808 (143)

Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? [PDF]

open access: yesAntimicrobial Agents and Chemotherapy
Ceftolozane/tazobactam is widely used against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, yet FDA-approved dosing relies on intermittent infusion and a fixed 2:1 ratio that assumes adequate β-lactamase inhibition. Tazobactam’s faster
Manjunath P. Pai   +7 more
doaj   +3 more sources

Trends in Pseudomonas aeruginosa In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016–2024 [PDF]

open access: yesAntibiotics
Objectives: To describe annual trends in the susceptibility of clinical isolates of Pseudomonas aeruginosa from Latin America to ceftolozane/tazobactam.
Mark G. Wise   +6 more
doaj   +3 more sources

Stability of Two Reserve Antibiotics in Elastomeric Pumps: Ceftazidime-Avibactam and Ceftolozane-Tazobactam [PDF]

open access: yesAntibiotics
Background/Objectives: Parenteral antibiotic therapy is indispensable in the treatment of several infections. The parenteral administration often leads to the need for prolonged hospitalization.
Joana Erdmann   +3 more
doaj   +3 more sources

Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess

open access: yesClinical Case Reports, 2018
Key Clinical Message Treatment of Pseudomonas aeruginosa remains challenging, despite the availability ceftolozane‐tazobactam. We report a treatment failure with ceftolozane‐tazobactam salvage therapy for pneumonia complicated by lung abscess.
Paul O. Lewis   +4 more
doaj   +2 more sources

Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies [PDF]

open access: yesAntibiotics
Introduction: The emergence and spread of multidrug-resistant infections has resulted in significant clinical and economic burdens. To address these infections, novel therapy combinations are needed.
Ignacio Martin-Loeches   +7 more
doaj   +2 more sources

Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions [PDF]

open access: yesJ Antimicrob Chemother
Background Pseudomonas aeruginosa biofilms limit the efficacy of currently available antibacterial therapies and pose significant clinical challenges.
Fu, Ying   +13 more
core   +2 more sources

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps

open access: yesCurrent Therapeutic Research, 2017
Background: Elastomeric pumps are often used to administer intravenous antibiotics in the outpatient setting, but effective infusion requires that the drug remain stable in solution throughout the procedure. Objective: To determine the chemical stability
Joseph Terracciano, PhD   +2 more
doaj   +2 more sources

Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024 [PDF]

open access: yesFrontiers in Cellular and Infection Microbiology
ObjectivesTo investigate the in vitro susceptibility of recent clinical Enterobacterales and Pseudomonas aeruginosa isolates collected in the Arabian Gulf region to ceftolozane/tazobactam, imipenem/relebactam, and comparator antimicrobial agents ...
Mark G. Wise   +5 more
doaj   +2 more sources

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)

open access: yesBrazilian Journal of Infectious Diseases, 2017
This study evaluated the in vitro activity of ceftolozane-tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections.
Michael A. Pfaller   +5 more
doaj   +2 more sources

A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa [PDF]

open access: yesJ Antimicrob Chemother
Objectives: To develop a scoring system to predict resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa strains isolated from respiratory specimens.
ÇAKIR, BANU   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy